In Vitro & In Vivo Diagnostic Substances
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| BlackRock, Inc. | 11.20M | $196.0M | 16.40% | +753.4K | 2026-06-30 |
| FMR LLC | 7.36M | $128.0M | 10.78% | +772.5K | 2026-06-30 |
| Newtyn Management, LLC | 6.63M | $116.0M | 9.70% | +2.07M | 2026-06-30 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | 4.14M | $72.0M | 6.05% | +103.7K | 2026-06-30 |
| NEUBERGER BERMAN GROUP LLC | 3.53M | $62.0M | 5.18% | +2.00M | 2026-06-30 |
| Invesco Ltd. | 3.47M | $60.0M | 5.09% | +356.0K | 2026-06-30 |
| AMERICAN CENTURY COMPANIES INC | 3.31M | $57.0M | 4.84% | +450.9K | 2026-06-30 |
| Rubric Capital Management LP | 3.31M | $57.0M | 4.84% | -- | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 3.07M | $53.0M | 4.49% | +17.3K | 2026-06-30 |
| STATE STREET CORP | 2.98M | $52.0M | 4.36% | +192.0K | 2026-06-30 |
